Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae142 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Laura M King und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Health, University of California, Berkeley, California, USA. Hauptthemen laut MEDLINE: Pneumococcal Vaccines, Anti-Bacterial Agents, Pneumococcal Infections, Streptococcus pneumoniae. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, CDC HHS.
Abstract (Originalsprache)
Background
In 2022–2023, 15- and 20-valent pneumococcal conjugate vaccines (PCV15/PCV20) were recommended for infants. We aimed to estimate the incidence of outpatient visits and antibiotic prescriptions in US children (≤17 years) from 2016–2019 for acute otitis media, pneumonia, and sinusitis associated with PCV15- and PCV20-additional (non-PCV13) serotypes to quantify PCV15/20 potential impacts.
Methods
We estimated the incidence of PCV15/20-additional serotype-attributable visits and antibiotic prescriptions as the product of all-cause incidence rates, derived from national health care surveys and MarketScan databases, and PCV15/20-additional serotype-attributable fractions. We estimated serotype-specific attributable fractions using modified vaccine-probe approaches incorporating incidence changes post-PCV13 and ratios of PCV13 versus PCV15/20 serotype frequencies, estimated through meta-analyses.
Results
Per 1000 children annually, PCV15-additional serotypes accounted for an estimated 2.7 (95% confidence interval, 1.8–3.9) visits and 2.4 (95% CI, 1.6–3.4) antibiotic prescriptions. PCV20-additional serotypes resulted in 15.0 (95% CI, 11.2–20.4) visits and 13.2 (95% CI, 9.9–18.0) antibiotic prescriptions annually per 1000 children. PCV15/20-additional serotypes account for 0.4% (95% CI, 0.2%–0.6%) and 2.1% (95% CI, 1.5%–3.0%) of pediatric outpatient antibiotic use.
Conclusions
Compared with PCV15-additional serotypes, PCV20-additional serotypes account for > 5 times the burden of visits and antibiotic prescriptions. Higher-valency PCVs, especially PCV20, may contribute to preventing pediatric pneumococcal respiratory infections and antibiotic use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Public Health, University of California, Berkeley, California, USA.
- Division of Bacterial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
- Department of Research and Evaluation, Southern California, Kaiser Permanente, Pasadena, California, USA.
ORCID-Profile: Laura M King, Sara Y Tartof
Förderung
- NIAID NIH HHS
- NIH HHS
- CDC HHS
- Centers for Disease Control and Prevention
- National Institutes of Health
Zitieren
APA
King, L. M., Andrejko, K. L., Kabbani, S., Tartof, S. Y., Hicks, L. A., Cohen, A. L., Kobayashi, M., & Lewnard, J. A. (2024). Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae142
Vancouver
King LM, Andrejko KL, Kabbani S, Tartof SY, Hicks LA, Cohen AL, et al. Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae142
BibTeX
@article{King2024,
author = {King, Laura M and Andrejko, Kristin L and Kabbani, Sarah and Tartof, Sara Y and Hicks, Lauri A and Cohen, Adam L and Kobayashi, Miwako and Lewnard, Joseph A},
title = {Outpatient Visits and Antibiotic Use Due to Higher-Valency Pneumococcal Vaccine Serotypes},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae142}
}
EUVIMED